A Phase 3 interventional study of Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ) and Prevnar13 in Infections, Meningococcal, sponsored by GlaxoSmithKline. Completed at 57 sites in 2 countries. Open to participants aged 6 Weeks to 12 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-20.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies in Meningococcal Infections by GlaxoSmithKline — none open to participants now, 1 under way, none of them phase 3. Meningococcal Infections · GlaxoSmithKline.
Among the 71 studies in Meningococcal Infections by GlaxoSmithKline, this one is the 13th largest by enrollment of the 67 interventional ones that give a count, is one of 4 that started in 2018, is one of 34 in phase 3, and was the 64th registered.
243 studies on the registry are indexed under Meningococcal Infections; 8 are open to participants now.
Browse Meningococcal Infections studies →None of the 71 studies in Meningococcal Infections by GlaxoSmithKline is open now. The open studies under Meningococcal Infections, anywhere →
Of the 7 Meningococcal Infections studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.
This study: 6 Weeks to 12 Weeks · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 26 · Phase 3 34 · Phase 4 6
First in 2002; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,196 is above the median of 456 across 214 interventional studies indexed under Meningococcal Infections.
Median enrollment 613 across the 67 interventional studies, 119 across the 4 observational. Of the 70 that completed or were terminated, 60 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 117 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 242 (90%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 71 studies in Meningococcal Infections by GlaxoSmithKline, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and immunogenicity of Bexsero (meningococcal group B vaccine-rMenB+OMV NZ) in North American infants 6 weeks through 12 weeks of age, when administered concomitantly with Pneumococcal conjugate vaccine (PCV 13) and other recommended routine infant vaccinesv(RIV).
This study is divided into three timepoints:
Epoch 1 - Primary: Day 1 to Day 301 Epoch 2 - Secondary: Day 301 to Day 331 Epoch 3 - Safety follow-up: Day 331 to the end of the study (Day 481 or Day 661). For participants who have not yet reached the 6-month safety follow-up after their last dose at the time Protocol Amendment 7 takes effect, visit 7 takes place on Day 481.
In addition to receiving the study vaccines, infants also receive non-study vaccines such as Diphtheria, tetanus toxoids and acellular pertussis adsorbed vaccine (DTPa, Infanrix) and Haemophilus influenzae type b Conjugate Vaccine (Hib, Hiberix) to minimize disruption to the standard infant vaccination schedule caused by participation in this study.
Participants receive rMenB+OMV NZ (Bexsero) concomitantly with PCV13 (Prevnar13) and other routine infant vaccines (Pediarix, Hiberix, Rotarix, M-M-R II, Varivax) at 2, 4, 6, and 12 months of age. Participants who have received three PCV13 doses before 12 months of age but have not yet received their fourth booster dose receive either PCV13 or PCV20 at 12 months of age (Visit 5).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All subjects must satisfy all the following criteria at study entry:
Exclusion Criteria:
If any exclusion criterion applies, the subject must not be included in the study:
Each subject must not have:
Abnormal function of the immune system resulting from:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301.
Biological: Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ) · Biological: Prevnar13 · Biological: Pediarix · Biological: Hiberix · Biological: Rotarix · Biological: M-M-R II · Biological: Varivax · Biological: Prevnar 20
Infant participants received PCV13 along with placebo, Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by PCV13, Placebo, Pediarix and Hiberix on Day 121 and PCV13/PCV20, Placebo M-M-R II and Varivax on Day 301.
Biological: Prevnar13 · Biological: Pediarix · Biological: Hiberix · Biological: Rotarix · Biological: M-M-R II · Biological: Varivax · Biological: Placebo (saline water) · Biological: Prevnar 20
Drug page: 4CMenB vaccineStudies of 4CMenB vaccine4CMenB vaccine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Bexsero was administered intramuscularly on Day 1, Day 61, Day 121 and Day 301.
Prevnar13 (PCV13) was administered intramuscularly on Day 1, Day 61, Day 121 and Day 301.
Pediarix (DTPa-HBV-IPV) was administered intramuscularly on Day 1, Day 61, and Day 121.
Hiberix (Hib) was administered intramuscularly on Day 1, Day 61, and Day 121.
Rotarix (HRV) was administered intramuscularly on Day 1 and Day 61.
M-M-R II (MMR) was administered intramuscularly on Day 301.
Varivax (VV) was administered intramuscularly on Day 301.
Placebo was administered intramuscularly on Day 1, Day 61, Day 121 and Day 301.
Prevnar 20 (PCV13) was administered intramuscularly as a booster dose on Day 301 group who have received 3 PCV13 doses before 12 months of age but have not received their fourth booster dose.
Number of Participants Reporting Any Solicited Administration Site Events After the First Vaccination Administered at Day 1
Assessed solicited administration site events include injection site tenderness (administration site pain), erythema (redness), swelling and induration. Any solicited administration site events = occurrence of the event regardless of intensity grade. Rotarix was administered orally; therefore, no administration site events were analyzed.
Time frame: Day 1 to Day 7
Number of Participants Reporting Any Solicited Systemic Events After the First Vaccination Administered at Day 1
Assessed systemic events include change in eating habits, sleepiness, vomiting, diarrhea, irritability, persistent crying, and fever, defined as body temperature greater than or equal to (≥)38.0°C/100.4°F. Any solicited systemic events = occurrence of the event regardless of intensity grade.
Time frame: Day 1 to Day 7
Number of Participants Reporting Any Solicited Administration Site Events After the Second Vaccination Administered at Day 61
Rotarix was administered orally; therefore, no administration site events were analyzed.
Time frame: Day 61 to Day 67
Number of Participants Reporting Any Solicited Systemic Events After the Second Vaccination Administered at Day 61
Time frame: Day 61 to Day 67
Number of Participants Reporting Any Solicited Administration Site Events After the Third Vaccination Administered at Day 121
Time frame: Day 121 to Day 127
Number of Participants Reporting Any Solicited Systemic Events After the Third Vaccination Administered at Day 121
Time frame: Day 121 to Day 127
Number of Participants Reporting Any Solicited Administration Site Events After the Fourth Vaccination Administered at Day 301
Time frame: Day 301 to Day 307
Number of Participants Reporting Any Solicited Systemic Events After the Fourth Vaccination Administered at Day 301
Time frame: Day 301 to Day 307
Number of Participants With Any Solicited Systemic AEs During the 30 Days After the Fourth Vaccination at Day 301
Systemic events assessed included rash, parotid/salivary gland swelling, and fever. These systemic adverse events were recorded for 30 days following MMR and VV vaccine administration. Any solicited systemic events = occurrence of the event regardless of intensity grade.
Time frame: Day 301 to Day 330
Number of Participants Reporting Any Unsolicited Adverse Events (AEs) After the First Vaccination Administered at Day 1
An unsolicited AEs is an AE that is not solicited using a subject diary and that is spontaneously communicated by the parent(s)/LAR(s) who has signed the informed consent or a solicited local or systemic AE that continues beyond the solicited period after vaccination. Any = occurrence of the event regardless of the intensity grade.
Time frame: Day 1 to Day 30
Number of Participants Reporting Any Unsolicited AEs After the Second Vaccination Administered at Day 61
Time frame: Day 61 to Day 90
Number of Participants Reporting Any Unsolicted AEs After the Third Vaccination Administered at Day 121
Time frame: Day 121 to Day 150
Number of Participants Reporting Any Unsolicited AEs After the Fourth Vaccination Administered at Day 301
Time frame: Day 301 to Day 330
Number of Participants Reporting Any SAEs, AEs Leading to Withdrawal, AESIs and MAAEs
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization and that results in disability/incapacity. An AE leading to withdrawal includes any AEs/SAEs collected and recorded from the time of the 1st receipt of study vaccines until study end which are identified as reasons for withdrawal of the participant from the study. AESIs are pre-defined (serious or non-serious) AEs of scientific and medical concern specific to the product or program which might warrant further investigation in order to characterize and understand it. MAAEs includes any AEs that required hospitalization, or an otherwise unscheduled visit to or from medical personnel for any reason, including emergency room visits.
Time frame: Day 1 up to study end (Day 481 for participants who have not reached 6-month follow-up at the time of Protocol Amendment 7; Day 661 for all others)
Percentage of Participants With Human Serum Bactericidal Assay (hSBA) Antibody Titers >= Lower Limit of Quantitation (LLOQ) for Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4) and M13520 (NHBA)
Serum bactericidal activity is assessed using human complement (hSBA) against Neisseria meningitidis serogroup B test strains: M14459 (fHbp); 96217 (NadA); NZ98/254 (PorA P1.4); M13520 (NHBA). The sufficiency of the immune response to rMenB+OMV NZ at one month after the third vaccination was to be demonstrated if the lower confidence limit for the percentage of participants achieving hSBA titers ≥ LLOQ is ≥ 60% for each of the M14459, 96217, NZ98/254, M13520 test strain. This outcome measure evaluated immune response to the rMenB+OMV NZ vaccine only, hence it was not applicable to the Placebo+PCV group.
Time frame: At Day 151 (1 month after the third vaccination)
Percentage of Participants With hSBA Titers >= LLOQ Against All Serogroup B Test Strains Combined (Composite Response)
The immune response to the rMenB+OMV NZ vaccine is assessed by measuring serum bactericidal activity using hSBA against four Neisseria meningitidis serogroup B test strains: M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA). The composite response is defined as the percentage of participants with hSBA titers ≥ Lower Limit of Quantitation (LLOQ) across all four strains combined. The sufficiency of the immune response to rMenB+OMV NZ at one month after the third vaccination was to be demonstrated if the lower confidence limit for the percentage of participants achieving hSBA titers ≥ LLOQ is ≥ 50% for all strains combined. This outcome measure evaluated immune response to the rMenB+OMV NZ vaccine only, hence it was not applicable to the Placebo+PCV group.
Time frame: At Day 151 (1 month after the third vaccination)
Percentage of Participants With hSBA Antibody Titers >= 8 for Strains M14459 (fHbp); 96217 (NadA); NZ98/254 (PorA P1.4); M13520 (NHBA) and >= 16 for Strain 96217
Serum bactericidal activity is assessed using human complement (hSBA) against Neisseria meningitidis serogroup B test strains: M14459 (fHbp); 96217 (NadA); NZ98/254 (PorA P1.4); M13520 (NHBA). The sufficiency of the immune response to rMenB+OMV NZ at one month after the 4th vaccination was to be demonstrated if the lower confidence limit for the percentage of participants achieving hSBA titers ≥ 8 (for strains M14459, NZ98/254, M13520) and ≥16 (for strain 96217) is ≥75% for each of the M14459, 96217, NZ98/254, M13520 test strains. This outcome measure evaluated immune response to the rMenB+OMV NZ vaccine only, hence it was not applicable to the Placebo+PCV group.
Time frame: At Day 331 (1 month after the fourth vaccination)
Percentage of Participants With hSBA Antibody Titers >= 8 for Strains M14459 (fHbp), NZ98/254 (PorA P1.4), and M13520 (NHBA) and >= 16 for Strain 96217 (NadA) (Composite Response Across All Strains)
The immune response to the rMenB+OMV NZ vaccine is assessed by measuring serum bactericidal activity using hSBA against four Neisseria meningitidis serogroup B test strains: M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA). The composite response is defined as the percentage of participants with hSBA titers ≥ Lower Limit of Quantitation (LLOQ) across all four strains combined. The sufficiency of the immune response to rMenB+OMV NZ at one month after the 4th vaccination was to be demonstrated if the lower confidence limit for the percentage of participants achieving hSBA titers ≥ 8 (for strains M14459, NZ98/254, M13520) and ≥16 (for strain 96217) is ≥65% for all strains combined. This outcome measure evaluated immune response to the rMenB+OMV NZ vaccine only, hence it was not applicable to the Placebo+PCV group.
Time frame: At Day 331 (1 month after the fourth vaccination)
Adjusted Geometric Mean Concentrations (GMCs) of Immunoglobubin (IgG) Antibodies Against 13 PCV13 Antigens at 1 Month After Third Vaccination
The immune response to PCV13 is evaluated by measuring IgG levels using electrochemiluminescence (ECL) assay. Adjusted GMCs are assessed for each of the 13 PCV13 antigens at 1 month after the third vaccination.
Time frame: At Day 151 (1 month after the third vaccination)
Adjusted GMCs of IgG Antibodies Against 13 PCV13 Antigens at 1 Month After the Fourth Vaccination Administered at Day 301
The immune response to PCV13 is evaluated by measuring IgG levels using ECL assay. Adjusted GMCs are assessed for each of the 13 PCV13 antigens at 1 month after the 4th vaccination.
Time frame: At Day 331 (1 month after the fourth vaccination)
Percentage of Participants With Serum Pneumococcal Anti-capsular Polysaccharide IgG >= 0.35 μg/mL
The immune response to PCV13 is evaluated by measuring the percentage of participants with serum IgG concentrations ≥ 0.35 μg/mL for each of the 13 PCV13 antigens at 1 month after the third and fourth vaccinations.
Time frame: At Day 151 (1 month after the third vaccination) and Day 331 (1 month after the fourth vaccination)
Adjusted GMCs Against 3 Pertussis Antigens (Pertussis Toxin [PT], Pertactin [PRN], Filamentous Hemagglutinin [FHA])
The immune response to DTaP-HBV-IPV (Pediarix) vaccine is evaluated. IgG concentrations for pertussis antigens (PT, FHA, PRN) are measured at 1 month after the third vaccination and are expressed as international units per millilitre (IU/mL).
Time frame: At Day 151 (1 month after the third vaccination)
Percentage of Participants With Antibodies Concentrations Against Hepatitis B Surface Antigen (AntiHBsAg) >= 10 mIU/mL
The immune response to DTaP-HBV-IPV vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for Hepatitis B (HepB) antigens are measured at 1 month after the third vaccination.
Time frame: At Day 151 (1 month after the third vaccination)
Percentage of Participants With Anti-diphtheria and Anti-tetanus Antibody Concentrations >= 0.1 IU/mL
The immune response to DTaP-HBV-IPV vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for diphtheria (D) and tetanus (T) were measured at 1 month after the third vaccination.
Time frame: At Day 151 (1 month after the third vaccination)
Percentage of Participants With Anti-polyribosyl-ribitol Phosphate (PRP) Concentration >= 0.15 µg/mL and >= 1 µg/mL
The immune response to Hib vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for Haemophilus influenzae type b (Hib) are measured at 1 month after the third vaccination.
Time frame: At Day 151 (1 month after the third vaccination)
Adjusted GMCs for Anti-measles Antibodies
The immune response to MMR vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for measles antigens are measured using adjusted GMCs at 1 month after fourth vaccination and are expressed as milli-International Units per milliliter (mIU/mL).
Time frame: At Day 331 (1 month after the fourth vaccination)
Adjusted GMCs for Anti-mumps Antibodies
The immune response to MMR vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for mumps antigens are measured using adjusted GMCs at 1 month after fourth vaccination.
Time frame: At Day 331 (1 month after the fourth vaccination)
Adjusted GMCs for Anti-rubella Antibodies
The immune response to MMR vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for rubella antigens are measured using adjusted GMCs at 1 month after fourth vaccination.
Time frame: At Day 331 (1 month after the fourth vaccination)
Adjusted GMCs for Anti-Varicella (VV) Antibodies
The immune response to varicella (VV) vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for varicella antigens are measured using GMCs at 1 month after fourth vaccination.
Time frame: At Day 331 (1 month after the fourth vaccination)
Percentage of Participants With hSBA Antibody Titers >= 5, >= 8 and >=16 for Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)
This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.
Time frame: At Day 151 (1 month after the third vaccination)
Percentage of Participants With hSBA Antibody Titers >= 5 and >= 8 for Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)
This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.
Time frame: At Day 301 (6 months after third vaccination)
Percentage of Participants With hSBA Antibody Titers >= 5 for Each of the Serogroup B Test Strain M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)
This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.
Time frame: At Day 331 (1 month after the fourth vaccination)
hSBA Geometric Mean Titers (GMTs) Against Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)
This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.
Time frame: At Day 151 (1 month after the third vaccination), Day 301 (6 months after the third vaccination), and Day 331 (1 month after the fourth vaccination)
hSBA Geometric Mean Ratios (GMRs) Over Pre Fourth Vaccination Against Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)
This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.
Time frame: At Day 331 (1 month after the fourth vaccination) compared to Day 301 (pre-fourth vaccination)
Percentage of Participants With hSBA Antibody Titers >= LLOQ for Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)
This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.
Time frame: At Day 301 (6 months after the third vaccination) and Day 331 (1 month after the fourth vaccination)
Percentage of Participants With 4-fold Rise in hSBA Titers for Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)
A 4-fold rise in hSBA titers is defined as - if pre-vaccination titer \<Limit of Detection (LOD), then a post-vaccination titer \>= 4 times the LOD or \>= LLOQ, whichever is greater; - if pre-vaccination titer is \>= LOD but \<LLOQ, then a post-vaccination titer \>= 4 times the LLOQ; - if pre-vaccination titer is \>= LLOQ, then a post-vaccination titer \>= 4 times the pre-vaccination titer, where pre-vaccination titer=pre-4th dose titers (Day 301). This outcome measure evaluated immune response to the rMenB+OMV NZ vaccine only, hence it was not applicable to the Placebo+PCV group.
Time frame: At Day 331 (1 month after the fourth vaccination) relative to Day 301 (pre-fourth vaccination)
Percentage of Participants With Anti-HBs Antibody Concentrations >= 100 mIU/mL
Time frame: At Day 151 (1 month after the third vaccination)
GMCs for Anti-HBsAg Antibodies
Time frame: At Day 151 (1 month after the third vaccination)
Percentage of Participants With Anti-diphtheria and Anti-tetanus Antibody Concentrations >= 1 IU/mL
Time frame: At Day 151 (1 month after the third vaccination)
GMCs for Anti-diphtheria and Anti-tetanus Antibodies
Time frame: At Day 151 (1 month after the third vaccination)
Percentage of Participants With Anti-polio Type 1, 2 and 3 Neutralization Antibody Titers >= 8
Time frame: At Day 151 (1 month after the third vaccination)
Percentage of Participants With Seroresponse for Anti-Varicella (VV), Anti-measles Virus, Anti-mumps Virus and Anti-rubella Virus Antibodies
Seroresponse is defined as post-vaccination anti-VZV virus, anti-measles virus, anti-mumps virus and anti-rubella virus antibody concentration \>= a protective threshold among participants who were seronegative (antibody concentration \< assay cut-off) before vaccination.
Time frame: At Day 331 (1 month after the fourth vaccination)
| Milestone | MenB+PCV Group | Placebo+PCV Group |
|---|---|---|
| Started | 781 | 403 |
| Completed | 642 | 326 |
| Not completed | 139 | 77 |
| Withdrew: Adverse event | 3 | 1 |
| Withdrew: Lost to follow-up | 32 | 25 |
| Withdrew: Consent withdrawal not due to aes | 54 | 18 |
| Withdrew: Migrated / moved from the study area | 21 | 12 |
| Withdrew: Not willing / not able to be contacted | 9 | 13 |
| Withdrew: Other | 13 | 5 |
| Withdrew: Protocol deviation | 7 | 3 |
Assessed solicited administration site events include injection site tenderness (administration site pain), erythema (redness), swelling and induration. Any solicited administration site events = occurrence of the event regardless of intensity grade. Rotarix was administered orally; therefore, no administration site events were analyzed.
| Participants | MenB+PCV Group | Placebo+PCV Group |
|---|---|---|
| Erythema, Bexsero | 156 | — |
| Erythema, Prevnar 13 | 100 | 39 |
| Erythema, Placebo | — | 25 |
| Erythema, Pediarix | 72 | 32 |
| Erythema, Hiberix | 74 | 17 |
| Induration, Bexsero | 204 | — |
| Induration, Prevnar 13 | 127 | 67 |
| Induration, Placebo | — | 22 |
| Induration, Pediarix | 70 | 34 |
| Induration, Hiberix | 77 | 20 |
| Swelling, Bexsero | 132 | — |
| Swelling, Prevnar 13 | 77 | 34 |
| Swelling, Placebo | — | 21 |
| Swelling, Pediarix | 53 | 21 |
| Swelling, Hiberix | 54 | 12 |
| Tenderness, Bexsero | 352 | — |
| Tenderness, Prevnar 13 | 310 | 107 |
| Tenderness, Placebo | 0 | 81 |
| Tenderness, Pediarix | 270 | 92 |
| Tenderness, Hiberix | 284 | 74 |
Assessed systemic events include change in eating habits, sleepiness, vomiting, diarrhea, irritability, persistent crying, and fever, defined as body temperature greater than or equal to (≥)38.0°C/100.4°F. Any solicited systemic events = occurrence of the event regardless of intensity grade.
| Participants | MenB+PCV Group | Placebo+PCV Group |
|---|---|---|
| Change in eating habits | 329 | 122 |
| Diarrhea | 173 | 84 |
| Irritability | 601 | 242 |
| Persistent crying | 248 | 89 |
| Sleepiness | 560 | 246 |
| Vomiting | 176 | 79 |
| Fever | 252 | 34 |
Rotarix was administered orally; therefore, no administration site events were analyzed.
| Participants | MenB+PCV Group | Placebo+PCV Group |
|---|---|---|
| Erythema, Bexsero | 200 | — |
| Erythema, Prevnar 13 | 129 | 62 |
| Erythema, Placebo | — | 44 |
| Erythema, Pediarix | 99 | 54 |
| Erythema, Hiberix | 86 | 41 |
| Induration, Bexsero | 213 | — |
| Induration, Prevnar 13 | 142 | 63 |
| Induration, Placebo | — | 32 |
| Induration, Pediarix | 109 | 55 |
| Induration, Hiberix | 80 | 32 |
| Swelling, Bexsero | 112 | — |
| Swelling, Prevnar 13 | 74 | 38 |
| Swelling, Placebo | — | 19 |
| Swelling, Pediarix | 52 | 33 |
| Tenderness, Bexsero | 269 | — |
| Swelling, Hiberix | 49 | 17 |
| Tenderness, Prevnar 13 | 227 | 81 |
| Tenderness, Placebo | 0 | 65 |
| Tenderness, Pediarix | 201 | 67 |
| Tenderness, Hiberix | 207 | 52 |
| Participants | MenB+PCV Group | Placebo+PCV Group |
|---|---|---|
| Change in eating habits | 238 | 90 |
| Diarrhea | 119 | 66 |
| Irritability | 514 | 215 |
| Persistent crying | 209 | 73 |
| Sleepiness | 455 | 183 |
| Vomiting | 104 | 49 |
| Fever | 269 | 64 |
| Participants | MenB+PCV Group | Placebo+PCV Group |
|---|---|---|
| Erythema, Bexsero | 181 | — |
| Erythema, Prevnar 13 | 127 | 71 |
| Erythema, Placebo | — | 43 |
| Erythema, Pediarix | 114 | 65 |
| Erythema, Hiberix | 97 | 38 |
| Induration, Bexsero | 187 | — |
| Induration, Prevnar 13 | 128 | 60 |
| Induration, Placebo | — | 26 |
| Induration, Pediarix | 124 | 70 |
| Induration, Hiberix | 86 | 28 |
| Swelling, Bexsero | 103 | — |
| Swelling, Prevnar 13 | 67 | 39 |
| Swelling, Placebo | — | 13 |
| Swelling, Pediarix | 55 | 28 |
| Swelling, Hiberix | 36 | 8 |
| Tenderness, Bexsero | 244 | — |
| Tenderness, Prevnar 13 | 210 | 66 |
| Tenderness, Placebo | — | 52 |
| Tenderness, Pediarix | 188 | 58 |
| Tenderness, Hiberix | 194 | 45 |
| Participants | MenB+PCV Group | Placebo+PCV Group |
|---|---|---|
| Change in eating habits | 205 | 94 |
| Diarrhea | 87 | 44 |
| Irritability | 454 | 179 |
| Persistent crying | 151 | 59 |
| Sleepiness | 326 | 142 |
| Vomiting | 88 | 46 |
| Fever | 216 | 55 |
| Participants | MenB+PCV Group | Placebo+PCV Group |
|---|---|---|
| Erythema, Bexsero | 180 | — |
| Erythema, Prevnar 13/20 | 119 | 37 |
| Erythema, Placebo | — | 25 |
| Erythema, MMR II | 64 | 24 |
| Erythema, Varivax | 62 | 20 |
| Induration, Bexsero | 179 | — |
| Induration, Prevnar 13/20 | 109 | 32 |
| Induration, Placebo | — | 24 |
| Induration, MMR II | 46 | 17 |
| Induration, Varivax | 38 | 15 |
| Swelling, Bexsero | 91 | — |
| Swelling, Prevnar 13/20 | 52 | 18 |
| Swelling, Placebo | — | 8 |
| Swelling, MMR II | 26 | 12 |
| Swelling, Varivax | 23 | 9 |
| Tenderness, Bexsero | 223 | — |
| Tenderness, Prevnar 13/20 | 181 | 35 |
| Tenderness, Placebo | — | 31 |
| Tenderness, MMR II | 130 | 28 |
| Tenderness, Varivax | 119 | 27 |
| Participants | MenB+PCV Group | Placebo+PCV Group |
|---|---|---|
| Change in eating habits | 219 | 75 |
| Diarrhea | 85 | 40 |
| Irritability | 401 | 153 |
| Persistent crying | 115 | 29 |
| Rash | 71 | 30 |
| Sleepiness | 273 | 96 |
| Vomiting | 60 | 32 |
| Fever | 118 | 22 |
Systemic events assessed included rash, parotid/salivary gland swelling, and fever. These systemic adverse events were recorded for 30 days following MMR and VV vaccine administration. Any solicited systemic events = occurrence of the event regardless of intensity grade.
| Participants | MenB+PCV Group | Placebo+PCV Group |
|---|---|---|
| Parotid/Salivary gland swelling | 20 | 17 |
| Rash | 206 | 95 |
| Fever | 197 | 70 |
An unsolicited AEs is an AE that is not solicited using a subject diary and that is spontaneously communicated by the parent(s)/LAR(s) who has signed the informed consent or a solicited local or systemic AE that continues beyond the solicited period after vaccination. Any = occurrence of the event regardless of the intensity grade.
| Participants | MenB+PCV Group | Placebo+PCV Group |
|---|---|---|
| Number of Participants Reporting Any Unsolicited Adverse Events (AEs) After the First Vaccination Administered at Day 1 | 214 | 103 |
| Participants | MenB+PCV Group | Placebo+PCV Group |
|---|---|---|
| Number of Participants Reporting Any Unsolicited AEs After the Second Vaccination Administered at Day 61 | 225 | 119 |
| Participants | MenB+PCV Group | Placebo+PCV Group |
|---|---|---|
| Number of Participants Reporting Any Unsolicted AEs After the Third Vaccination Administered at Day 121 | 230 | 120 |
| Participants | MenB+PCV Group | Placebo+PCV Group |
|---|---|---|
| Number of Participants Reporting Any Unsolicited AEs After the Fourth Vaccination Administered at Day 301 | 248 | 144 |
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization and that results in disability/incapacity. An AE leading to withdrawal includes any AEs/SAEs collected and recorded from the time of the 1st receipt of study vaccines until study end which are identified as reasons for withdrawal of the participant from the study. AESIs are pre-defined (serious or non-serious) AEs of scientific and medical concern specific to the product or program which might warrant further investigation in order to characterize and understand it. MAAEs includes any AEs that required hospitalization, or an otherwise unscheduled visit to or from medical personnel for any reason, including emergency room visits.
| Participants | MenB+PCV Group | Placebo+PCV Group |
|---|---|---|
| AEs leading to withdrawal | 3 | 1 |
| SAEs | 35 | 19 |
| AESIs | 6 | 3 |
| MAAEs | 626 | 329 |
Serum bactericidal activity is assessed using human complement (hSBA) against Neisseria meningitidis serogroup B test strains: M14459 (fHbp); 96217 (NadA); NZ98/254 (PorA P1.4); M13520 (NHBA). The sufficiency of the immune response to rMenB+OMV NZ at one month after the third vaccination was to be demonstrated if the lower confidence limit for the percentage of participants achieving hSBA titers ≥ LLOQ is ≥ 60% for each of the M14459, 96217, NZ98/254, M13520 test strain. This outcome measure evaluated immune response to the rMenB+OMV NZ vaccine only, hence it was not applicable to the Placebo+PCV group.
| Percentage of participants | MenB+PCV Group |
|---|---|
| M14459 (fHbp) | 92.2 (88.6 to 94.9) |
| 96217 (NadA) | 99.4 (97.9 to 99.9) |
| NZ98/254 (PorA) | 73.5 (68.2 to 78.3) |
| M13520 (NHBA) | 53.0 (47.3 to 58.6) |
The immune response to the rMenB+OMV NZ vaccine is assessed by measuring serum bactericidal activity using hSBA against four Neisseria meningitidis serogroup B test strains: M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA). The composite response is defined as the percentage of participants with hSBA titers ≥ Lower Limit of Quantitation (LLOQ) across all four strains combined. The sufficiency of the immune response to rMenB+OMV NZ at one month after the third vaccination was to be demonstrated if the lower confidence limit for the percentage of participants achieving hSBA titers ≥ LLOQ is ≥ 50% for all strains combined. This outcome measure evaluated immune response to the rMenB+OMV NZ vaccine only, hence it was not applicable to the Placebo+PCV group.
| Percentage of participants | MenB+PCV Group |
|---|---|
| Percentage of Participants With hSBA Titers >= LLOQ Against All Serogroup B Test Strains Combined (Composite Response) | 42.7 (37.0 to 48.6) |
Serum bactericidal activity is assessed using human complement (hSBA) against Neisseria meningitidis serogroup B test strains: M14459 (fHbp); 96217 (NadA); NZ98/254 (PorA P1.4); M13520 (NHBA). The sufficiency of the immune response to rMenB+OMV NZ at one month after the 4th vaccination was to be demonstrated if the lower confidence limit for the percentage of participants achieving hSBA titers ≥ 8 (for strains M14459, NZ98/254, M13520) and ≥16 (for strain 96217) is ≥75% for each of the M14459, 96217, NZ98/254, M13520 test strains. This outcome measure evaluated immune response to the rMenB+OMV NZ vaccine only, hence it was not applicable to the Placebo+PCV group.
| Percentage of participants | MenB+PCV Group |
|---|---|
| M14459 (fHbp) | 89.0 (85.8 to 91.7) |
| 96217 (NadA) | 99.6 (98.5 to 100) |
| NZ98/254 (PorA P1.4) | 83.2 (79.4 to 86.5) |
| M13520 (NHBA) | 76.6 (72.5 to 80.4) |
The immune response to the rMenB+OMV NZ vaccine is assessed by measuring serum bactericidal activity using hSBA against four Neisseria meningitidis serogroup B test strains: M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA). The composite response is defined as the percentage of participants with hSBA titers ≥ Lower Limit of Quantitation (LLOQ) across all four strains combined. The sufficiency of the immune response to rMenB+OMV NZ at one month after the 4th vaccination was to be demonstrated if the lower confidence limit for the percentage of participants achieving hSBA titers ≥ 8 (for strains M14459, NZ98/254, M13520) and ≥16 (for strain 96217) is ≥65% for all strains combined. This outcome measure evaluated immune response to the rMenB+OMV NZ vaccine only, hence it was not applicable to the Placebo+PCV group.
| Percentage of participants | MenB+PCV Group |
|---|---|
| Percentage of Participants With hSBA Antibody Titers >= 8 for Strains M14459 (fHbp), NZ98/254 (PorA P1.4), and M13520 (NHBA) and >= 16 for Strain 96217 (NadA) (Composite Response Across All Strains) | 63.2 (58.5 to 67.7) |
The immune response to PCV13 is evaluated by measuring IgG levels using electrochemiluminescence (ECL) assay. Adjusted GMCs are assessed for each of the 13 PCV13 antigens at 1 month after the third vaccination.
| Microgram per milliliter(µg/mL) | MenB+PCV Group | Placebo+PCV Group |
|---|---|---|
| Serotype 1 | 1.6 (1.4 to 1.9) | 1.5 (1.3 to 1.8) |
| Serotype 3 | 0.5 (0.4 to 0.6) | 0.5 (0.4 to 0.6) |
| Serotype 4 | 1.1 (0.9 to 1.3) | 1.1 (1.0 to 1.3) |
| Serotype 5 | 1.0 (0.8 to 1.2) | 1.0 (0.8 to 1.2) |
| Serotype 6 | 2.4 (2.0 to 2.8) | 2.5 (2.1 to 2.9) |
| Serotype 6B | 1.5 (1.1 to 1.9) | 1.8 (1.4 to 2.3) |
| Serotype 7F | 2.8 (2.4 to 3.3) | 2.9 (2.5 to 3.3) |
| Serotype 9V | 1.3 (1.1 to 1.6) | 1.4 (1.2 to 1.6) |
| Serotype 14 | 5.9 (4.7 to 7.4) | 5.8 (4.8 to 7.2) |
| Serotype 18C | 1.5 (1.3 to 1.8) | 1.5 (1.3 to 1.8) |
| Serotype 19A | 1.7 (1.4 to 2.0) | 1.8 (1.6 to 2.2) |
| Serotype 19F | 2.5 (2.1 to 2.9) | 2.5 (2.2 to 2.9) |
| Serotype 23F | 0.9 (0.7 to 1.1) | 1.0 (0.8 to 1.2) |
The immune response to PCV13 is evaluated by measuring IgG levels using ECL assay. Adjusted GMCs are assessed for each of the 13 PCV13 antigens at 1 month after the 4th vaccination.
| µg/mL | MenB+PCV Group | Placebo+PCV Group |
|---|---|---|
| Serotype 1 | 1.8 (1.5 to 2.1) | 1.8 (1.6 to 2.1) |
| Serotype 3 | 0.5 (0.4 to 0.6) | 0.5 (0.5 to 0.6) |
| Serotype 4 | 1.5 (1.2 to 1.8) | 1.7 (1.4 to 2.0) |
| Serotype 5 | 1.8 (1.5 to 2.1) | 1.8 (1.6 to 2.1) |
| Serotype 6 | 5.2 (4.4 to 6.1) | 6.0 (5.2 to 7.0) |
| Serotype 6B | 4.7 (3.9 to 5.6) | 5.4 (4.6 to 6.4) |
| Serotype 7F | 3.7 (3.2 to 4.4) | 4.6 (4.0 to 5.3) |
| Serotype 9V | 2.3 (2.0 to 2.8) | 2.6 (2.2 to 3.1) |
| Serotype 14 | 7.0 (5.8 to 8.4) | 7.1 (6.0 to 8.4) |
| Serotype 18C | 2.0 (1.7 to 2.4) | 2.2 (1.9 to 2.6) |
| Serotype 19A | 4.5 (3.8 to 5.3) | 5.5 (4.7 to 6.4) |
| Serotype 19F | 4.8 (4.1 to 5.7) | 5.0 (4.3 to 5.9) |
| Serotype 23F | 1.9 (1.5 to 2.3) | 1.9 (1.6 to 2.3) |
The immune response to PCV13 is evaluated by measuring the percentage of participants with serum IgG concentrations ≥ 0.35 μg/mL for each of the 13 PCV13 antigens at 1 month after the third and fourth vaccinations.
| Percentage of participants | MenB+PCV Group | Placebo+PCV Group |
|---|---|---|
| Serotype 1, At Day 151 | 99.2 (97.1 to 99.9) | 97.1 (94.4 to 98.7) |
| Serotype 1, At Day 331 | 98.7 (96.2 to 99.7) | 97.1 (94.1 to 98.8) |
| Serotype 3, At Day 151 | 59.8 (53.4 to 66.0) | 61.5 (55.5 to 67.3) |
| Serotype 3, At Day 331 | 63.6 (56.9 to 69.8) | 69.5 (63.2 to 75.2) |
| Serotype 4, At Day 151 | 94.3 (90.6 to 96.8) | 96.0 (93.0 to 98.0) |
| Serotype 4, At Day 331 | 97.8 (94.9 to 99.3) | 96.7 (93.5 to 98.6) |
| Serotype 5, At Day 151 | 91.0 (86.7 to 94.3) | 87.4 (82.9 to 91.1) |
| Serotype 5, At Day 331 | 96.0 (92.5 to 98.2) | 98.8 (96.4 to 99.7) |
| Serotype 6, At Day 151 | 99.2 (97.1 to 99.9) | 99.6 (98.0 to 100) |
| Serotype 6, At Day 331 | 100 (98.4 to 100) | 99.6 (97.7 to 100) |
| Serotype 6B, At Day 151 | 89.8 (85.2 to 93.3) | 92.4 (88.7 to 95.3) |
| Serotype 6B, At Day 331 | 100 (98.4 to 100) | 99.6 (97.7 to 100) |
| Serotype 7F, At Day 151 | 99.6 (97.7 to 100) | 100 (98.7 to 100) |
| Serotype 7F, At Day 331 | 99.6 (97.5 to 100) | 100 (98.5 to 100) |
| Serotype 9V, At Day 151 | 95.1 (91.6 to 97.4) | 93.2 (89.5 to 95.8) |
| Serotype 9V, At Day 331 | 98.7 (96.1 to 99.7) | 98.8 (96.4 to 99.7) |
| Serotype 14, At Day 151 | 98.0 (95.3 to 99.3) | 98.6 (96.4 to 99.6) |
| Serotype 14, At Day 331 | 100 (98.4 to 100) | 100 (98.5 to 100) |
| Serotype 18C, At Day 151 | 97.5 (94.7 to 99.1) | 96.8 (93.9 to 98.5) |
| Serotype 18C, At Day 331 | 99.1 (96.8 to 99.9) | 99.2 (97.0 to 99.9) |
| Serotype 19A, At Day 151 | 96.7 (93.6 to 98.6) | 98.6 (96.4 to 99.6) |
| Serotype 19A, At Day 331 | 100 (98.4 to 100) | 99.6 (97.7 to 100) |
| Serotype 19F, At Day 151 | 99.6 (97.7 to 100) | 100 (98.7 to 100) |
| Serotype 19F, At Day 331 | 100 (98.4 to 100) | 100 (98.5 to 100) |
| Serotype 23F, At Day 151 | 87.3 (82.5 to 91.2) | 87.0 (82.5 to 90.7) |
| Serotype 23F, At Day 331 | 97.3 (94.3 to 99.0) | 97.1 (94.1 to 98.8) |
The immune response to DTaP-HBV-IPV (Pediarix) vaccine is evaluated. IgG concentrations for pertussis antigens (PT, FHA, PRN) are measured at 1 month after the third vaccination and are expressed as international units per millilitre (IU/mL).
| IU/mL | MenB+PCV Group | Placebo+PCV Group |
|---|---|---|
| PT | 50.3 (45.1 to 56.0) | 59.6 (53.2 to 66.8) |
| FHA | 106.7 (96.4 to 118.0) | 133.1 (119.5 to 148.2) |
| Pertactin | 41.7 (36.1 to 48.1) | 65.7 (56.4 to 76.4) |
The immune response to DTaP-HBV-IPV vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for Hepatitis B (HepB) antigens are measured at 1 month after the third vaccination.
| Percentage of participants | MenB+PCV Group | Placebo+PCV Group |
|---|---|---|
| Percentage of Participants With Antibodies Concentrations Against Hepatitis B Surface Antigen (AntiHBsAg) >= 10 mIU/mL | 100 (96.5 to 100) | 99.3 (96.0 to 100) |
The immune response to DTaP-HBV-IPV vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for diphtheria (D) and tetanus (T) were measured at 1 month after the third vaccination.
| Percentage of participants | MenB+PCV Group | Placebo+PCV Group |
|---|---|---|
| Tetanus Toxoid | 100 (98.4 to 100) | 100 (97.5 to 100) |
| Diphtheria Toxoid | 99.5 (97.5 to 100) | 100 (97.3 to 100) |
The immune response to Hib vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for Haemophilus influenzae type b (Hib) are measured at 1 month after the third vaccination.
| Percentage of participants | MenB+PCV Group | Placebo+PCV Group |
|---|---|---|
| >= 0.15 µg/mL | 98.3 (96.3 to 99.4) | 97.7 (95.1 to 99.2) |
| >= 1 µg/mL | 87.0 (83.0 to 90.4) | 84.1 (79.1 to 88.3) |
The immune response to MMR vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for measles antigens are measured using adjusted GMCs at 1 month after fourth vaccination and are expressed as milli-International Units per milliliter (mIU/mL).
| mIU/mL | MenB+PCV Group | Placebo+PCV Group |
|---|---|---|
| Adjusted GMCs for Anti-measles Antibodies | 877.3 (743.7 to 1035.0) | 873.5 (732.2 to 1042.0) |
The immune response to MMR vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for mumps antigens are measured using adjusted GMCs at 1 month after fourth vaccination.
| Arbitrary Units per milliliter (AU/mL) | MenB+PCV Group | Placebo+PCV Group |
|---|---|---|
| Adjusted GMCs for Anti-mumps Antibodies | 744.5 (628.5 to 882.0) | 856.8 (715.0 to 1026.7) |
The immune response to MMR vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for rubella antigens are measured using adjusted GMCs at 1 month after fourth vaccination.
| IU/mL | MenB+PCV Group | Placebo+PCV Group |
|---|---|---|
| Adjusted GMCs for Anti-rubella Antibodies | 57.7 (50.0 to 66.6) | 54.0 (46.3 to 63.0) |
The immune response to varicella (VV) vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for varicella antigens are measured using GMCs at 1 month after fourth vaccination.
| mIU/mL | MenB+PCV Group | Placebo+PCV Group |
|---|---|---|
| Adjusted GMCs for Anti-Varicella (VV) Antibodies | 1283.8 (1137.4 to 1449.2) | 1208.9 (1060.5 to 1378.2) |
This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.
| Percentage of participants | MenB+PCV Group |
|---|---|
| M14459 (fHbp), >= 5 | 92.2 (89.6 to 94.3) |
| M14459 (fHbp), >= 8 | 82.9 (79.4 to 86.0) |
| M14459 (fHbp), >= 16 | 50.5 (46.2 to 54.8) |
| 96217 (NadA), >= 5 | 99.6 (98.6 to 100) |
| 96217 (NadA), >= 8 | 99.6 (98.6 to 100) |
| 96217 (NadA), >= 16 | 99.4 (98.3 to 99.9) |
| NZ98/254 (PorA P1.4), >= 5 | 77.7 (74.0 to 81.1) |
| NZ98/254 (PorA P1.4), >= 8 | 61.8 (57.6 to 65.9) |
| NZ98/254 (PorA P1.4), >= 16 | 31.1 (27.2 to 35.1) |
| M13520 (NHBA), >= 5 | 60.4 (56.2 to 64.5) |
| M13520 (NHBA), >= 8 | 32.4 (28.5 to 36.4) |
| M13520 (NHBA), >= 16 | 9.4 (7.1 to 12.1) |
This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.
| Percentage of participants | MenB+PCV Group |
|---|---|
| M14459 (fHbp), >= 5 | 14.5 (11.6 to 17.9) |
| M14459 (fHbp), >= 8 | 4.8 (3.2 to 7.1) |
| 96217 (NadA) >= 5 | 97.8 (96.1 to 98.9) |
| 96217 (NadA), >= 8 | 96.4 (94.4 to 97.9) |
| NZ98/254 (PorA P1.4), >= 5 | 20.2 (16.8 to 23.8) |
| NZ98/254 (PorA P1.4), >= 8 | 12.2 (9.6 to 15.3) |
| M13520 (NHBA), >= 5 | 10.2 (7.8 to 13.1) |
| M13520 (NHBA) >= 8 | 5.9 (4.1 to 8.3) |
This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.
| Percentage of participants | MenB+PCV Group |
|---|---|
| M14459 (fHbp), >= 5 | 94.5 (92.1 to 96.4) |
| 96217 (NadA), >= 5 | 99.6 (98.5 to 99.9) |
| NZ98/254 (PorA P1.4), >= 5 | 89.6 (86.6 to 92.1) |
| M13520 (NHBA), >= 5 | 91.5 (88.7 to 93.8) |
This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.
| Titer | MenB+PCV Group |
|---|---|
| M14459 (fHbp), Day 151 | 15.1 (13.7 to 16.7) |
| M14459 (fHbp), Day 301 | 3.0 (2.8 to 3.2) |
| M14459 (fHbp), Day 331 | 24.3 (21.3 to 27.8) |
| 96217 (NadA), Day 151 | 488.2 (437.3 to 545.0) |
| 96217 (NadA), Day 301 | 89.1 (77.3 to 102.7) |
| 96217 (NadA), Day 331 | 1349.0 (1195.3 to 1522.5) |
| NZ98/254 (PorA P1.4), Day 151 | 10.1 (8.9 to 11.4) |
| NZ98/254 (PorA P1.4), Day 301 | 3.8 (3.5 to 4.0) |
| NZ98/254 (PorA P1.4), Day 331 | 20.3 (17.3 to 23.7) |
| M13520 (NHBA), Day 151 | 5.5 (5.0 to 6.0) |
| M13520 (NHBA), Day 301 | 3.5 (3.3 to 3.7) |
| M13520 (NHBA), Day 331 | 12.7 (11.2 to 14.4) |
This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.
| Ratio | MenB+PCV Group |
|---|---|
| M14459 (fHbp) | 8.7 (7.6 to 10.0) |
| 96217 (NadA) | 17.4 (15.1 to 20.1) |
| NZ98/254 (PorA P1.4) | 5.5 (4.7 to 6.5) |
| M13520 (NHBA) | 3.9 (3.4 to 4.4) |
This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.
| Percentage of participants | MenB+PCV Group |
|---|---|
| M14459 (fHbp), Day 301 | 14.5 (11.6 to 17.9) |
| M14459 (fHbp), Day 331 | 94.5 (92.1 to 96.4) |
| 96217 (NadA), Day 301 | 94.1 (91.6 to 96.0) |
| 96217 (NadA), Day 331 | 99.6 (98.5 to 99.9) |
| M13520 (NHBA), Day 301 | 8.5 (6.3 to 11.2) |
| M13520 (NHBA), Day 331 | 86.1 (82.8 to 89.0) |
| NZ98/254 (PorA P1.4), Day 301 | 17.5 (14.4 to 21.0) |
| NZ98/254 (PorA P1.4), Day 331 | 87.6 (84.4 to 90.3) |
A 4-fold rise in hSBA titers is defined as - if pre-vaccination titer \<Limit of Detection (LOD), then a post-vaccination titer \>= 4 times the LOD or \>= LLOQ, whichever is greater; - if pre-vaccination titer is \>= LOD but \<LLOQ, then a post-vaccination titer \>= 4 times the LLOQ; - if pre-vaccination titer is \>= LLOQ, then a post-vaccination titer \>= 4 times the pre-vaccination titer, where pre-vaccination titer=pre-4th dose titers (Day 301). This outcome measure evaluated immune response to the rMenB+OMV NZ vaccine only, hence it was not applicable to the Placebo+PCV group.
| Percentage of participants | MenB+PCV Group |
|---|---|
| M14459 (fHbp), Day 331 | 72.0 (67.5 to 76.1) |
| 96217 (NadA), Day 331 | 94.8 (92.2 to 96.7) |
| M13520 (NHBA), Day 331 | 36.1 (31.8 to 40.7) |
| NZ98/254 (PorA P1.4), Day 331 | 54.2 (49.5 to 58.9) |
| Percentage of participants | MenB+PCV Group | Placebo+PCV Group |
|---|---|---|
| Percentage of Participants With Anti-HBs Antibody Concentrations >= 100 mIU/mL | 98.1 (93.3 to 99.8) | 96.4 (91.7 to 98.8) |
| mIU/mL | MenB+PCV Group | Placebo+PCV Group |
|---|---|---|
| GMCs for Anti-HBsAg Antibodies | 2201.0 (1554.7 to 3116.0) | 2404.8 (1803.1 to 3207.3) |
| Percentage of participants | MenB+PCV Group | Placebo+PCV Group |
|---|---|---|
| Tetanus Toxoid | 67.0 (60.4 to 73.1) | 69.2 (61.0 to 76.7) |
| Diphtheria Toxoid | 40.0 (33.5 to 46.8) | 55.1 (46.4 to 63.7) |
| IU/mL | MenB+PCV Group | Placebo+PCV Group |
|---|---|---|
| Tetanus Toxoid | 1.5 (1.3 to 1.8) | 1.6 (1.3 to 1.9) |
| Diphtheria Toxoid | 0.9 (0.8 to 1.1) | 1.2 (1.0 to 1.5) |
| Percentage of participants | MenB+PCV Group | Placebo+PCV Group |
|---|---|---|
| Polio 1 | 100 (96.4 to 100) | 100 (97.0 to 100) |
| Polio 2 | 99.1 (94.9 to 100) | 100 (96.9 to 100) |
| Polio 3 | 100 (96.3 to 100) | 99.1 (95.1 to 100) |
Seroresponse is defined as post-vaccination anti-VZV virus, anti-measles virus, anti-mumps virus and anti-rubella virus antibody concentration \>= a protective threshold among participants who were seronegative (antibody concentration \< assay cut-off) before vaccination.
| Percentage of participants | MenB+PCV Group | Placebo+PCV Group |
|---|---|---|
| Mumps | 81.6 (77.2 to 85.5) | 85.9 (80.2 to 90.4) |
| Measles | 94.8 (91.9 to 96.9) | 97.9 (94.7 to 99.4) |
| Rubella | 86.4 (82.3 to 89.8) | 83.9 (78.1 to 88.7) |
| VZV gE | 97.3 (95.0 to 98.7) | 97.5 (94.3 to 99.2) |
Collected over Solicited AEs: Day 1 to Day 7 post each vaccination, Solicited systemic AEs of salivary gland swelling, fever and rash: Day 1 to Day 30 post fourth vaccination; Unsolicited AEs: Day 1 to Day 30 post each vaccination. All-cause mortality, SAEs, AEs leading to withdrawal, AESIs and MAAEs: For participants not reaching Day 481 by Protocol Amendment 7: first vaccination (Day 1) to Day 481, for participants past Day 481 by the amendment: first vaccination (Day 1) to Day 661. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MenB+PCV Group | 0/781 (0%) | 35/781 (4.5%) | 771/781 (98.7%) |
| Placebo+PCV Group | 0/403 (0%) | 19/403 (4.7%) | 389/403 (96.5%) |
| Event | MenB+PCV Group | Placebo+PCV Group |
|---|---|---|
| BronchiolitisInfections and infestations | 4/781 | 2/403 |
| Respiratory syncytial virus bronchiolitisInfections and infestations | 3/781 | 2/403 |
| Respiratory syncytial virus infectionInfections and infestations | 2/781 | 2/403 |
| GastroenteritisInfections and infestations | 3/781 | 1/403 |
| Febrile convulsionNervous system disorders | 3/781 | 1/403 |
| PyrexiaGeneral disorders | 2/781 | 0/403 |
| InfluenzaInfections and infestations | 2/781 | 1/403 |
| PneumoniaInfections and infestations | 2/781 | 1/403 |
| SeizureNervous system disorders | 2/781 | 0/403 |
| LymphadenitisBlood and lymphatic system disorders | 0/781 | 1/403 |
| Event | MenB+PCV Group | Placebo+PCV Group |
|---|---|---|
| IrritabilityPsychiatric disorders | 713/781 | 330/403 |
| SomnolenceNervous system disorders | 681/781 | 319/403 |
| Administration site painGeneral disorders | 582/781 | 201/403 |
| HypophagiaMetabolism and nutrition disorders | 543/781 | 216/403 |
| PyrexiaGeneral disorders | 521/781 | 172/403 |
| Administration site indurationGeneral disorders | 480/781 | 180/403 |
| Administration site erythemaGeneral disorders | 460/781 | 170/403 |
| CryingGeneral disorders | 432/781 | 163/403 |
| DiarrhoeaGastrointestinal disorders | 334/781 | 178/403 |
| Administration site swellingGeneral disorders | 322/781 | 122/403 |
| Age, Continuous(Weeks) | MenB+PCV Group | Placebo+PCV Group | Total |
|---|---|---|---|
| Mean | 8.6 ± 1.0 | 8.8 ± 1.0 | 8.7 ± 1.0 |
| Sex: Female, Male(Participants) | MenB+PCV Group | Placebo+PCV Group | Total |
|---|---|---|---|
| Female | 380 | 196 | 576 |
| Male | 401 | 207 | 608 |
| Race/Ethnicity, Customized(Participants) | MenB+PCV Group | Placebo+PCV Group | Total |
|---|---|---|---|
| American Indian or Alaska Native | 17 | 4 | 21 |
| Asian | 39 | 21 | 60 |
| Black or African American | 84 | 33 | 117 |
| Native Hawaiian or Other Pacific Islander | 3 | 1 | 4 |
| White | 531 | 288 | 819 |
| Other (Not specified) | 107 | 56 | 163 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Jul 2018 to primary completion in Dec 2024, 77 months.
Results were first posted in Feb 2026, 1 year 1 month after primary completion.
Of 46 industry-sponsored phase 3 interventional studies under Meningococcal Infections, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 40. This study's 77 months is above that.
Counting every sponsor, half of 46 studies reached it within 15 months; a quarter within 8 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.